SCHEMBL786488

SCHEMBL786488

CC(C)(O)CC[NH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8718395 0.78
SCHEMBL37987 0.76 ALDH1A1 (1.00)
Ammonia Solution, Strong SCHEMBL28802926 0.72 ALDH1A1 (0.91)
SCHEMBL786896 0.72
SCHEMBL1269985 0.69 ALDH1A1 (0.69)
SCHEMBL42680 0.69
SCHEMBL9138582 0.69 ALDH1A1 (0.83)
SCHEMBL2818804 0.69 ALDH1A1 (0.69)
SCHEMBL3040312 0.67 ALDH1A1 (0.64)
SCHEMBL7754200 0.67 ALDH1A1 (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2953951-B1 N2-SUBSTITUTED-N6-(6-ARYL-PYRIDINE-3-YLMETHYL)-9-CYCLOPENTYL-9H-PURINE-2,6-DIAMINE DERIVATIVES AS TUMOR SUPPRESSOR P53 ACTIVATORS FOR INHIBITING ANGIOGENESIS AND FOR TREATING CANCER UNIV PALACKEHO (CZ) 2017-05-03 EP claimed
US-20150368248-A1 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS BIOPATTERNS S.R.O. (CZ) 2015-12-24 US claimed
EP-2953951-A2 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS Univerzita palackeho V Olomouci (CZ) 2015-12-16 EP claimed
WO-2014121764-A2 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2014-08-14 WO claimed
CN-111212647-B Dihydro oxadiazinones 拜耳股份有限公司 2024-05-14 CN disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 US disclosed
EP-3661517-B1 DIHYDROOXADIAZINONES BAYER AG (DE) 2023-09-13 EP disclosed
US-20230017200-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2023-01-19 US disclosed
US-20220396554-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2022-12-15 US disclosed
EP-4038062-A1 N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT Kainos Medicine, Inc. (KR) 2022-08-10 EP disclosed
CN-114466844-A N- (1H-imidazol-2-yl) benzamide compounds and pharmaceutical compositions containing the same as active ingredient 康佳诺医疗科技发展有限公司 2022-05-10 CN disclosed
WO-2021066559-A1 N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT KAINOS MEDICINE, INC. (KR) 2021-04-08 WO disclosed
US-20120070512-A1 Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives BIOPATTERNS, S.R.O (CZ) 2012-03-22 US disclosed
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2011-11-24 US disclosed
WO-2011105628-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-01 WO disclosed
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
EP-2118066-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA Takeda Pharmaceutical Company Limited (JP) 2009-11-18 EP disclosed
WO-2008099794-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-21 WO disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed
US-3998827-A HYPOTENSIVE AGENTS THE UPJOHN COMPANY (US) 1976-12-21 US disclosed